Core Viewpoint - The major shareholder of Conch Cement, Conch Group, has significantly increased its stake for the first time in approximately 12 years, while the company has changed its stock repurchase plan to cancellation, indicating a strategic shift amidst ongoing industry challenges [1][2]. Company Summary - Conch Group increased its shareholding from 36.40% to 37.05% by purchasing 34.76 million A-shares, valued between 7.86 billion to 9.26 billion yuan based on share price fluctuations during the purchase period [1][2]. - The company plans to change the purpose of 22.24 million A-shares, previously intended for resale, to cancellation, which will reduce registered capital and potentially enhance earnings per share (EPS) [2][3]. - Conch Cement's revenue has declined from a peak of 176.29 billion yuan in 2020 to 82.53 billion yuan in 2025, a drop of 53.19%, while net profit decreased from 35.16 billion yuan to 8.11 billion yuan during the same period [3][4]. - Despite a 9.33% revenue decline in 2025 compared to 2024, net profit increased by 5.42%, attributed to effective cost control measures [3][4]. - The sales gross margin improved to 24.16% in 2025, up from 21.7% in 2024, while the net profit margin rose to 9.53% from 8.42% [3][4]. Industry Summary - The cement industry is experiencing a downturn, with demand expected to continue declining, although the rate of decline may slow due to supply-side policies and market consolidation [5][6]. - The domestic cement demand is projected to remain weak in 2025, with a further drop in capacity utilization and prices expected to fluctuate at low levels [5][6]. - The supply-side policies, including "overproduction control" and carbon market regulations, are anticipated to lead to the exit of excess and outdated production capacity, potentially improving profitability in the long term [6][5]. - The overall cement market is in a slow downward trend, with production expected to be around 70% of peak levels in 2025, and infrastructure investment is projected to decline for the first time since 2014 [6][5].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yuanxin Yongfeng have heavily invested in Tiger Med, holding a total of 293,400 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of 745,200 CNY, with a total floating profit of 950,600 CNY over the past three days [2][8]. - Yuanxin Yongfeng Multi-Strategy Fund (004148) holds 185,900 shares, representing 3.18% of the fund's net value, while Yuanxin Yongfeng Consumption Upgrade Fund (004934) holds 107,500 shares, accounting for 3.3% of the fund's net value [3][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Longxin Fund has a significant holding in Tiger Med, with its Longxin Xianrui Mixed A Fund (519937) holding 50,000 shares, representing 0.71% of the fund's net value, making it the seventh-largest holding [2][5]. - The fund has realized a floating profit of approximately 127,000 CNY today, with a total floating profit of 162,000 CNY during the three-day increase [2][5]. - The Longxin Xianrui Mixed A Fund was established on June 2, 2016, with a current size of 16.30 million CNY. Year-to-date returns are 1.52%, with a one-year return of 5.08% and a cumulative return of 43.7% since inception [2][5]. Fund Manager Performance - The fund manager, Ye Song, has a tenure of 15 years and 3 days, managing assets totaling 1.397 billion CNY, with the best fund return during his tenure being 98.51% and the worst being -16.83% [3][6]. - Co-manager Cheng Fang has a tenure of 5 years and 88 days, managing assets of 538 million CNY, with the best return of 16.42% and the worst return of 1.3% during his tenure [3][6].

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, established on December 15, 2004, and listed on August 17, 2012. The company specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, regulatory submissions, and various medical services [1][7]. Stock Performance - On March 27, Tiger Med's stock rose by 5%, reaching a price of 53.32 CNY per share, with a trading volume of 696 million CNY and a turnover rate of 2.35%. The total market capitalization is 45.91 billion CNY. The stock has experienced a cumulative increase of 6.82% over the past three days [1][7]. Shareholder Insights - E Fund's ChiNext ETF (159915) is among the top ten shareholders of Tiger Med, having reduced its holdings by 1.88 million shares in the third quarter, now holding 11.26 million shares, which represents 1.63% of the circulating shares. The estimated floating profit today is approximately 28.60 million CNY, with a total floating profit of 36.48 million CNY over the past three days [2][8]. Fund Performance - E Fund's ChiNext ETF (159915) has a total asset size of 100.45 billion CNY, with a year-to-date return of 2.38%, ranking 1280 out of 5563 in its category. Over the past year, it has achieved a return of 55.52%, ranking 386 out of 4429, and since inception, it has returned 274.08% [2][8]. Fund Holdings - Six funds under E Fund have significant holdings in Tiger Med, totaling 2.56 million shares. Based on the previous day's closing price of 50.78 CNY, the estimated floating profit today is around 650,660 CNY, with a total floating profit of 829,980 CNY over the past three days [4][10]. Fund Manager Profiles - The fund managers of E Fund's ChiNext ETF (159915) are Cheng Xi and Liu Shurong. Cheng has been in the position for 9 years and 327 days, managing assets totaling 252.07 billion CNY, with the best return during his tenure being 131.04%. Liu has been managing 127.68 billion CNY for 8 years and 255 days, achieving a best return of 194.12% [3][9].

Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xiangcai Fund has a significant holding in Tiger Med, with the Xiangcai Changxing Flexible Allocation Mixed A Fund (009169) holding 20,900 shares, representing 4.73% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 53,100 CNY today and a total of 67,700 CNY during the three-day price increase [2][5]. - The Xiangcai Changxing Flexible Allocation Mixed A Fund was established on April 23, 2020, with a current size of 9.6681 million CNY. Year-to-date, it has incurred a loss of 5.96%, ranking 7640 out of 8898 in its category, while it has achieved a 7.24% return over the past year, ranking 5586 out of 8181 [2][5]. Fund Manager Performance - The fund managers of Xiangcai Changxing Flexible Allocation Mixed A are Che Guanglu and Bao Jiamin. Che has a tenure of 14 years and 30 days, managing assets totaling 489 million CNY, with the best fund return of 54.67% and the worst return of -40.29% during his tenure [3][6]. - Bao has a tenure of 2 years and 24 days, managing assets of 662 million CNY, with the best fund return of 60.96% and the worst return of -12.82% during her tenure [3][6].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][6]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6][7]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [7]. Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) has entered the top ten circulating shareholders of Tiger Med, holding 8.78 million shares, which is 1.27% of the circulating shares. The estimated floating profit today is approximately 22.30 million CNY, with a total floating profit of 28.44 million CNY over the three-day increase [2][8]. - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.26 billion CNY. Year-to-date, it has experienced a loss of 3.16%, ranking 3698 out of 5563 in its category, while it has gained 17.24% over the past year, ranking 2622 out of 4429 [2][8]. Fund Performance - The fund manager of Huatai-PB CSI 300 ETF is Liu Jun, who has a tenure of 16 years and 301 days, managing assets totaling 550.93 billion CNY. The best fund return during his tenure is 205.53%, while the worst is -45.64% [3][8]. - Huatai-PB Medical Health A (005805) has increased its holdings in Tiger Med by 5,950 shares, totaling 273,500 shares, which represents 5.02% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is about 694,700 CNY, with a total floating profit of 886,100 CNY over the three-day increase [4][9]. - The Huatai-PB Medical Health A fund was established on June 25, 2018, with a current scale of 251 million CNY. It has incurred a loss of 5.46% year-to-date, ranking 7497 out of 8898, while gaining 4.27% over the past year, ranking 6365 out of 8181 [4][9]. Fund Manager Insights - The fund manager of Huatai-PB Medical Health A is Zhang Hong, who has a tenure of 6 years and 145 days, managing assets totaling 2.21 billion CNY. The best fund return during his tenure is 105.24%, while the worst is -19.01% [5][10].

Core Viewpoint - Tiger Med has seen a significant stock price increase, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yinhua Fund have significant holdings in Tiger Med, totaling 6.2985 million shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 15.9982 million CNY, with a total floating profit of 20.4072 million CNY over the past three days [2][7]. - The "Innovation Drug" fund holds 6.25881 million shares, representing 0.8481% of the circulating shares and 2.86% of the fund's net value, while the "Yinhua Healthcare Mixed A" fund holds 39,700 shares, accounting for 0.0053% of the circulating shares and 5.37% of the fund's net value [3][8].

Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under China International Capital Corporation (CICC) holds a significant position in Tiger Med. The CICC New Medicine A Fund (006981) held 89,800 shares in the fourth quarter, representing 5.9% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 228,100 yuan today, with a total floating profit of 291,000 yuan during the three-day increase [2][5]. - The CICC New Medicine A Fund was established on May 14, 2019, with a current scale of 68.32 million yuan. Year-to-date, it has experienced a loss of 6.84%, ranking 4,764 out of 5,563 in its category; over the past year, it has gained 8.47%, ranking 3,376 out of 4,429; and since inception, it has achieved a return of 44.49% [2][5]. Fund Manager Information - The fund manager of CICC New Medicine A is Ding Tianyu, who has been in the position for 5 years and 89 days. The total asset size of the fund is 205 million yuan, with the best return during his tenure being 2.35% and the worst return being -30.51% [3][6][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Huashan National Bio-Medical ETF (159508) has increased its holdings in Tiger Med by 12,600 shares, bringing the total to 39,400 shares, which constitutes 5.58% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund was established on June 29, 2023, with a current size of 40.08 million CNY. Year-to-date, it has experienced a loss of 6.74%, ranking 4,743 out of 5,563 in its category [2][5]. Fund Manager Performance - The fund manager, Su Qingyun, has a tenure of 9 years and 101 days, managing assets totaling 10.863 billion CNY. The best fund return during this period is 102.21%, while the worst return is -62.44% [3][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Six funds under Galaxy Fund hold a total of 2.8611 million shares of Tiger Med, with a floating profit of approximately 7.27 million yuan based on the stock price increase [2][6]. - The largest holding fund, Galaxy Medical Mixed A, reduced its holdings by 7,600 shares in the fourth quarter, now holding 722,300 shares, which represents 9.44% of the fund's net value [3][7]. - Other funds, such as Galaxy Industry Mixed A and Galaxy Research Selected Mixed A, also reduced their holdings but still maintain significant positions, with floating profits of approximately 175.21 thousand yuan and 163.53 thousand yuan, respectively, over the past three days [4][8].